MicroRNA367 negatively regulates the inflammatory response of microglia by targeting IRAK4 in intracerebral hemorrhage

Journal of Neuroinflammation

Zhao Yang²  Lina Zhong²  Tonggang Su¹  Li Lin¹  Hanchao Shen¹  Bangqing Yuan¹ 

[1] Department of Neurosurgery, The 476th Hospital of PLA, Fuzhou 350025, Fujian, China;Department of Neurology, Yongchuan Hospital, Chongqing Medical University, Chongqing 402160, China

关键词: ICH;    IRAK4;    Microglia;    Inflammation;    microRNA367;   

Others  :  1234438
DOI  :  10.1186/s12974-015-0424-3

 received in 2015-08-31, accepted in 2015-10-31,  发布年份 2015

【 摘 要 】

Background

Intracerebral hemorrhage (ICH) induces microglial activation and the release of inflammatory cytokines, leading to inflammation in the brain. IRAK4, an essential component of the MyD88-dependent pathway, activates subsets of divergent signaling pathways in inflammation.

Methods

In the experiment, microglia were stimulated with erythrocyte lysates, and then miR-367, IRAK4, NF-ĸB activation and downstream proinflammatory mediator production were analyzed. In addition, inflammation, brain edema, and neurological functions in ICH mice were also assessed.

Results

Here, we report that ICH downregulated miR-367 expression but upregulated IRAK4 expression in primary microglia. We also demonstrate that miR-367 suppressed IRAK4 expression by directly binding its 3′-untranslated region. MiR-367 inhibited NF-ĸB activation and downstream proinflammatory mediator production. Knocking down IRAK4 in microglia significantly decreased the IRAK4 expression and inhibited the NF-ĸB activation and the downstream production of proinflammatory mediators. In addition, our results indicate that miR-367 could inhibit expression of proinflammatory cytokines, reduce brain edema, and improve neurological functions in ICH mice.

Conclusions

In conclusion, our study demonstrates that miR-367/IRAK4 pathway plays an important role in microglial activation and neuroinflammation in ICH. Our finding also suggests that miR-367 might represent a potential therapeutic target for ICH.

【 授权许可】

   
2015 Yuan et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB: Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009, 114:4777-83.
• [2]Fernandes H, Gregson BA, Siddique MS, Mendelow AD: Testing the ICH score. Stroke 2002, 33:1455-6.
• [3]Fernandes HM, Siddique S, Banister K, Chambers I, Wooldridge T, Gregson B, Mendelow AD: Continuous monitoring of ICP and CPP following ICH and its relationship to clinical, radiological and surgical parameters. Acta Neurochir Suppl 2000, 76:463-6.
• [4]Chen HS, Hsieh CF, Chau TT, Yang CD, Chen YW: Risk factors of in-hospital mortality of intracerebral hemorrhage and comparison of ICH scores in a Taiwanese population. Eur Neurol 2011, 66:59-63.
• [5]Sato S, Koga M, Yamagami H, Okuda S, Okada Y, Kimura K, Shiokawa Y, Nakagawara J, Furui E, Hasegawa Y, Kario K, Arihiro S, Nagatsuka K, Minematsu K, Toyoda K: Conjugate eye deviation in acute intracerebral hemorrhage: stroke acute management with urgent risk-factor assessment and improvement—ICH (SAMURAI-ICH) study. Stroke 2012, 43:2898-903.
• [6]Godoy DA, Boccio A: ICH score in a rural village in the Republic of Argentina. Stroke 2003, 34:e150-1.
• [7]Aronowski J, Zhao X: Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke 2011, 42:1781-6.
• [8]Thiex R: Future perspectives on the fibrinolytic therapy of intracerebral hemorrhages. Cent Nerv Syst Agents Med Chem 2011, 11:150-6.
• [9]Di Napoli M, Godoy DA, Campi V, del Valle M, Pinero G, Mirofsky M, Popa-Wagner A, Masotti L, Papa F, Rabinstein AA: C-reactive protein level measurement improves mortality prediction when added to the spontaneous intracerebral hemorrhage score. Stroke 2011, 42:1230-6.
• [10]Loiarro M, Ruggiero V, Sette C: Targeting TLR/IL-1R signalling in human diseases. Mediators Inflamm 2010, 2010:674363.
• [11]Hubbard LL, Moore BB. IRAK-M regulation and function in host defense and immune homeostasis. Infect Dis Rep. 2010;2:e9.
• [12]Noris M, Cassis P, Azzollini N, Cavinato R, Cugini D, Casiraghi F, Aiello S, Solini S, Cassis L, Mister M, Todeschini M, Abbate M, Benigni A, Trionfini P, Tomasoni S, Mele C, Garlanda C, Polentarutti N, Mantovani A, Remuzzi G: The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts. J Immunol 2009, 183:4249-60.
• [13]Heinz LX, Rebsamen M, Rossi DC, Staehli F, Schroder K, Quadroni M, Gross O, Schneider P, Tschopp J: The death domain-containing protein Unc5CL is a novel MyD88-independent activator of the pro-inflammatory IRAK signaling cascade. Cell Death Differ 2012, 19:722-31.
• [14]Chiang EY, Yu X, Grogan JL: Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types. J Immunol 2011, 186:1279-88.
• [15]Lin SC, Lo YC, Wu H: Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010, 465:885-90.
• [16]Lu LF, Gasteiger G, Yu IS, Chaudhry A, Hsin JP, Lu Y, Bos PD, Lin LL, Zawislak CL, Cho S, Sun JC, Leslie CS, Lin SW, Rudensky AY: A single miRNA-mRNA interaction affects the immune response in a context- and cell-type-specific manner. Immunity 2015, 43:52-64.
• [17]Benderska N, Dittrich AL, Knaup S, Rau TT, Neufert C, Wach S, Fahlbusch FB, Rauh M, Wirtz RM, Agaimy A, Srinivasan S, Mahadevan V, Rummele P, Rapti E, Gazouli M, Hartmann A, Schneider-Stock R: miRNA-26b overexpression in ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis 2015, 21(9):2039-51.
• [18]Zeng FR, Tang LJ, He Y, Garcia RC: An update on the role of miRNA-155 in pathogenic microbial infections. Microbes Infect 2015, 17(9):613-21.
• [19]Oner T, Yenmis G, Tombulturk K, Cam C, Kucuk OS, Yakicier MC, Dizman D, Sultuybek GK: Association of pre-miRNA-499 rs3746444 and pre-miRNA-146a rs2910164 polymorphisms and susceptibility to Behcet’s disease. Genet Test Mol Biomarkers 2015, 19:424-30.
• [20]Dhanasekaran S, Doherty TM, Kenneth J: Comparison of different standards for real-time PCR-based absolute quantification. J Immunol Methods 2010, 354:34-9.
• [21]Culp WC, Woods SD, Brown AT, Lowery JD, Hennings LJ, Skinner RD, Borrelli MJ, Roberson PK: Three variations in rabbit angiographic stroke models. J Neurosci Methods 2013, 212:322-8.
• [22]Zazulia AR: Hydrocephalus in ICH: what do we really know? Neurocrit Care 2008, 8:233-4.
• [23]Wartenberg KE, Mayer SA: Reducing the risk of ICH enlargement. J Neurol Sci 2007, 261:99-107.
• [24]Mitchell P, Gregson BA, Vindlacheruvu RR, Mendelow AD: Surgical options in ICH including decompressive craniectomy. J Neurol Sci 2007, 261:89-98.
• [25]Leclerc JL, Lampert AS, Diller MA, Immergluck JB, Dore S. Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery. ASN Neuro. 2015;7.
• [26]Hollig A, Weinandy A, Nolte K, Clusmann H, Rossaint R, Coburn M: Experimental subarachnoid hemorrhage in rats: comparison of two endovascular perforation techniques with respect to success rate, confounding pathologies and early hippocampal tissue lesion pattern. PLoS One 2015, 10:e0123398.
• [27]Urday S, Kimberly WT, Beslow LA, Vortmeyer AO, Selim MH, Rosand J, Simard JM, Sheth KN: Targeting secondary injury in intracerebral haemorrhage—perihaematomal oedema. Nat Rev Neurol 2015, 11:111-22.
• [28]Carstens JL, Lovisa S, Kalluri R: Microenvironment-dependent cues trigger miRNA-regulated feedback loop to facilitate the EMT/MET switch. J Clin Invest 2014, 124:1458-60.
• [29]Ayyadurai S, Charania MA, Xiao B, Viennois E, Zhang Y, Merlin D: Colonic miRNA expression/secretion, regulated by intestinal epithelial PepT1, plays an important role in cell-to-cell communication during colitis. PLoS One 2014, 9:e87614.
• [30]Nielsen S, Akerstrom T, Rinnov A, Yfanti C, Scheele C, Pedersen BK, Laye MJ: The miRNA plasma signature in response to acute aerobic exercise and endurance training. PLoS One 2014, 9:e87308.
• [31]Sarma NJ, Tiriveedhi V, Subramanian V, Shenoy S, Crippin JS, Chapman WC, Mohanakumar T: Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway. PLoS One 2012, 7:e50826.
• [32]Xie W, Li Z, Li M, Xu N, Zhang Y: miR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivo. Biochem Biophys Res Commun 2013, 430:647-52.
• [33]Chen PY, Qin L, Barnes C, Charisse K, Yi T, Zhang X, Ali R, Medina PP, Yu J, Slack FJ, Anderson DG, Kotelianski V, Wang F, Tellides G, Simons M: FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep 2012, 2:1684-96.
• [34]Li X: IRAK4 in TLR/IL-1R signaling: possible clinical applications. Eur J Immunol 2008, 38:614-8.
• [35]Kim TW, Staschke K, Bulek K, Yao J, Peters K, Oh KH, Vandenburg Y, Xiao H, Qian W, Hamilton T, Min B, Sen G, Gilmour R, Li X: A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med 2007, 204:1025-36.
• [36]Davidson DJ, Currie AJ, Bowdish DM, Brown KL, Rosenberger CM, Ma RC, Bylund J, Campsall PA, Puel A, Picard C, Casanova JL, Turvey SE, Hancock RE, Devon RS, Speert DP: IRAK-4 mutation (Q293X): rapid detection and characterization of defective post-transcriptional TLR/IL-1R responses in human myeloid and non-myeloid cells. J Immunol 2006, 177:8202-11.
• [37]Motegi H, Shimo Y, Akiyama T, Inoue J: TRAF6 negatively regulates the Jak1-Erk pathway in interleukin-2 signaling. Genes Cells 2011, 16:179-89.
• [38]Zhou F, Zhang X, van Dam H, Ten Dijke P, Huang H, Zhang L: Ubiquitin-specific protease 4 mitigates Toll-like/interleukin-1 receptor signaling and regulates innate immune activation. J Biol Chem 2012, 287:11002-10.
• [39]Rakoff-Nahoum S, Kong Y, Kleinstein SH, Subramanian S, Ahern PP, Gordon JI, Medzhitov R: Analysis of gene-environment interactions in postnatal development of the mammalian intestine. Proc Natl Acad Sci U S A 2015, 112:1929-36.
• [40]Zhu Z, Xu Y, Zhao J, Liu Q, Feng W, Fan J, Wang P: miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-beta signalling pathway. Br J Cancer 2015, 112:1367-75.
• [41]Kuo CH, Deng JH, Deng Q, Ying SY: A novel role of miR-302/367 in reprogramming. Biochem Biophys Res Commun 2012, 417:11-6.